Clinical trial

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

NCT01215227

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Preladenant Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Rasagiline Normalized identity: rasagilineView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo to preladenant Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo to rasagiline Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2010-11-18

PhasePHASE3

Conditions

Parkinson Diseaseverified · MONDO: Parkinson disease

Idiopathic Parkinson Diseaseunresolved

Interventions

PreladenantDRUG

RasagilineDRUG · verified · RxNorm: rasagiline

Placebo to preladenantDRUG

Placebo to rasagilineDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01215227 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.